"Contrast harms the kidneys"—this belief has been present among patients for years, and sometimes also among physicians. In clinical practice, it may raise concerns about imaging examinations and ...

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best NASDAQ stocks with the highest upside potential.

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...

Contrast agents could provide an efficient means for physicians to detect infections through imaging, rather than unnecessarily prescribing antibiotics, according to a Technology Review report. Two ...

Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...

Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings.

A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...

CHICAGO--(BUSINESS WIRE)--Ultrasound contrast agents show promise for detecting and evaluating uterine disorders and prostate cancers, scientists reported today at the annual Advances in Contrast ...

GE HealthCare has dosed the first patient in a Phase 2/3 trial of a manganese-based MRI contrast agent and secured FDA clearance for three next-generation SIGNA MRI systems. The contrast agent aims to ...

Researchers from the University of Washington School of Medicine in Seattle, Mayo Clinic in Rochester, Minn., the University of California San Francisco and Nextrast found that a new oral contrast ...

Nanomedicine. 2015;10(2):321-341. Delivery: "Go where we want." The contrast agent must be able to be delivered in vivo and transported to the site of interest. Nontoxic: "Do no harm along the way." ...